Free β-CTX peptide blocksβ-CTX recombinant mAb (S0B3621) binding with coating antigen (another β-CTX peptide)
Coating antigen: β-CTX peptide, 0.5 µg/ml
S0B3621: 200 ng/ml
Free β-CTX peptide dilutions start from 2 μg/ml.
IC50= 178.5 ng/ml.
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | β-CTX |
| Synonyms | b-CTx; bCTXI; bCTX-I; B-Cr; BCL; Type I Collagen C-Telopeptide-Related Fraction |
| Immunogen | Synthetic Peptide |
| Clone Number | SDT-2488-4 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | Competitive ELISA |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Purity | >95% by HPLC |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt, 2 to 8 °C as supplied |
Background
β-CTX, or β-C-terminal telopeptide of type I collagen, is a specific peptide fragment released during the breakdown of bone collagen. It serves as a direct and sensitive biomarker for bone resorption, the process where osteoclasts break down bone tissue.The detection of β-CTX in blood serum, typically via immunoassay, holds major clinical significance in managing bone metabolism disorders. Its primary application is in osteoporosis. Measuring β-CTX levels helps assess overall bone turnover rate, evaluate fracture risk, and most importantly, monitor the effectiveness of antiresorptive therapy (like bisphosphonates). A significant drop in β-CTX after treatment initiation indicates a positive pharmacological response. It is also valuable in diagnosing and monitoring other conditions with altered bone turnover, such as Paget's disease and bone metastases.
Picture
Picture
Compete ELISA
